Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Mometasone Furoate Nasal Spray (internal)

This product is suitable for treating seasonal or perennial rhinitis in adults, adolescents and children aged 3 to 11. For patients with moderate to severe seasonal allergic rhinitis, it is recommended to use this product as preventive treatment 2-4 weeks before the beginning of the pollen season. More role
App download minus 10 yuan
Common name:
Mometasone Furoate Nasal Spray
Product No.:
C14200158282
Approval No.:
H20140100 (inquired by the State Drug Administration)
Jianke price:
¥149.64
Product specification:
fifty μ G * 140 press fifty μ G * 60 press
Manufacturer:
Schering plough labo N.V. (Belgium)
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Mometasone Furoate Nasal Spray (internal)
Main raw materials Main ingredients: mometasone furoate.
Main role This product is suitable for treating seasonal or perennial rhinitis in adults, adolescents and children aged 3 to 11. For patients with moderate to severe seasonal allergic rhinitis, it is recommended to use this product as preventive treatment 2-4 weeks before the beginning of the pollen season.
Product specification fifty μ G * 140 press
Usage and dosage Seasonal allergic or perennial rhinitis: Usually, press the sprayer for 6-7 times as a starting point until the uniform spray is observed, then the nasal cavity is administered, and the 100mg is sprayed with a mixture of methyl furacate and methyl acid, which is equivalent to that of amethasone furfurate, which is equivalent to 50. μ G, if the sprayer is suspended for more than 14 days, it should be restarted after application. Shake the container thoroughly before each application. 1. Adults (including elderly patients) and youth: the commonly recommended amount for prevention and treatment is 2 sprays per nostril (50 sprays per spray) μ g) Once a day (200 in total) μ g) , after the symptoms are controlled, the dose can be reduced to 1 spray per nostril (total 100 μ g) , which can maintain the curative effect. If the symptoms are not effectively controlled, the dose can be increased to 4 sprays per nostril (total 400) μ g) , reduce the dose after symptom control. It can produce obvious clinical effect 12 hours after the first administration. 2. Children aged 3 to 11: the recommended dosage is 1 spray per nostril (50 for each spray) μ g) Once a day (total 100) μ g)。
manufacturing enterprise Schering plough labo N.V. (Belgium)
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Mometasone Furoate Nasal Spray (internal)

[common name] Mometasone Furoate Nasal Spray

[specification and model] fifty μ G * 140 press

[manufacturer] Schering plough labo N.V. (Belgium)

[drug type] Western medicine

[approval No.] H20140100

[validity period] 24 months

[functional indications] This product is suitable for treating seasonal or perennial rhinitis in adults, adolescents and children aged 3 to 11. For patients with moderate to severe seasonal allergic rhinitis, it is recommended to use this product as preventive treatment 2-4 weeks before the beginning of the pollen season.

[usage and dosage] Seasonal allergic or perennial rhinitis: Usually, press the sprayer for 6-7 times as a starting point until the uniform spray is observed, then the nasal cavity is administered, and the 100mg is sprayed with a mixture of methyl furacate and methyl acid, which is equivalent to that of amethasone furfurate, which is equivalent to 50. μ G, if the sprayer is suspended for more than 14 days, it should be restarted after application. Shake the container thoroughly before each application. 1. Adults (including elderly patients) and youth: the commonly recommended amount for prevention and treatment is 2 sprays per nostril (50 sprays per spray) μ g) Once a day (200 in total) μ g) , after the symptoms are controlled, the dose can be reduced to 1 spray per nostril (total 100 μ g) , which can maintain the curative effect. If the symptoms are not effectively controlled, the dose can be increased to 4 sprays per nostril (total 400) μ g) , reduce the dose after symptom control. It can produce obvious clinical effect 12 hours after the first administration. 2. Children aged 3 to 11: the recommended dosage is 1 spray per nostril (50 for each spray) μ g) Once a day (total 100) μ g)。

[adverse reactions] Seasonal allergic or perennial rhinitis: 1. in clinical studies, local adverse reactions associated with this product (adult and adolescent patients) include nosebleeds, such as obvious bleeding, bloody mucus and blood spots (8%), pharyngitis (4%), nasal burning sensation (2%) and nasal irritation (2%). These adverse reactions are commonly seen when corticosteroid nasal spray is used. Epistaxis is generally self limiting and mild. The incidence is higher than that of placebo (5%), but close to or lower than that of cortical stimulation (15%) of positive control. Other reactions are equivalent to that of placebo. 2. In pediatric patients, adverse reactions such as headache (3%), epistaxis (6%), nasal irritation (2%) and runny nose (2%) were comparable to placebo. Nasal inhalation of mometasone furoate monohydrate rarely leads to immediate allergic reaction, and there are few reports of allergy and angioedema.

[precautions] 1. For local infection involving nasal mucosa, this product should not be used without treatment. 2. Because corticosteroids can inhibit the wound, patients who have recently undergone nasal surgery or trauma should not use nasal corticosteroids before the wound heals. 3. After 12 months of treatment with this product, there is no atrophy of nasal mucosa. Meanwhile, mometasone furoate can restore the nasal mucosa to normal histological manifestations. Like any drug used for a long time, patients who use this product for several months or more should regularly check the nasal mucosa. If local fungal infection occurs in the nasopharynx, this product should be stopped or appropriate treatment should be given. Persistent nasopharynx irritation may be an indication of discontinuation of this product. 4. For patients with active or static respiratory tuberculosis infection, untreated fungi, bacteria, systemic virus infection or ocular herpes simplex, use this product with caution. 5. No inhibition of hypothalamic pituitary adrenocortical (HPA) axis was found after long-term use of this product, but careful attention should be paid to patients who used this product instead of systemic corticosteroids for a long time. These patients can cause adrenal insufficiency by stopping the use of systemic corticosteroids, and the function of hypothalamic pituitary adrenocortical axis can be restored after several months. If these patients have symptoms and signs of adrenal insufficiency, they should resume the use of systemic corticosteroids, give other treatment and take appropriate measures. 6. When replacing this product with corticosteroids for the whole body, although the nasal symptoms of some patients are relieved, the withdrawal symptoms of corticosteroids during the whole body medication, such as joint (and / or) muscle pain, fatigue and depression, should be encouraged to continue to use this product. In addition, the conversion of systemic hormone to local nasal application can also expose the original allergic diseases, such as allergic conjunctivitis and eczema, which are inhibited by systemic medication. 7. The immune function of patients receiving corticosteroid treatment may be inhibited, so they should be alert to the risk of some infections (such as chickenpox and measles). If this happens, they must get the guidance of doctors. 8. After intranasal aerosol inhalation of corticosteroids, rare cases of perforation of nasal septum or elevated intracranial pressure have been reported. Please read the instructions carefully and follow the doctor's advice.

[taboo] It is forbidden to be allergic to any ingredient in this product (active ingredient: mometasone furoate monohydrate; inactive ingredient: cellulose, glycerol, sodium citrate dihydrate, citric acid hydrate, polysorbate 80, benzalkonium chloride, phenylethanol and pure water).

[listing Permit Holder] Schering ploughlabon. V. (Belgium)

[packaging unit] bottle

[main ingredients] Main ingredients: mometasone furoate.

[character] Mometasone Furoate Nasal Spray is a quantitative hand held spray device with white to white suspending agents.

[applicable population] unlimited

[medication for pregnant and lactating women] Adequate or good controlled studies have not been conducted for pregnant women. Like other nasal glucocorticoid preparations, for pregnant women, nursing mothers or women of childbearing age, this product can only be used when the benefits to the mother, fetus or baby exceed the possible hazards. For infants whose mothers receive glucocorticoids during pregnancy, it is necessary to observe whether there is adrenal hypofunction.

[medication for children] Clinical controlled studies have shown that nasal glucocorticoids may slow down the growth rate of children. In the absence of laboratory evidence of hypothalamic pituitary adrenal (HPA) axis inhibition, the observed phenomenon suggests that the growth rate is a more sensitive indicator of systemic glucocorticoid exposure in children than the commonly used HPA axis function test. The long-term effects of this slowdown in growth associated with nasal glucocorticoids, including the effect on adult height, are unknown. The potential effect on growth after cessation of nasal glucocorticoid treatment has not been fully studied. Routine tests (such as height test) should be carried out for children receiving nasal glucocorticoids (including 50mg of this product). The potential impact of prolonged treatment on growth should be measured by the clinical benefits obtained and the safety and effectiveness of alternative non glucocorticoid therapy. In order to reduce the systemic effect of intranasal administration of glucocorticoids (including 50mg of this product), the minimum effective dose of each patient should be determined.

[medication for elderly patients] Elderly patients: a total of 203 patients over 64 years old (64 to 86 years old) were treated with this product, 50mg for 3 months. The adverse reactions reported in this population are similar in type and scope of influence to those reported in young patients.

[storage] Store at 2 ℃ to 25 ℃.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Mometasone Furoate Nasal Spray (internal)

    ¥149.64

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!